Tirzepatide is linked to lower cardiovascular risk than dulaglutide for adults with type 2 diabetes and atherosclerotic ...

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in ...

A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide.

New national guidance for managing cholesterol and other blood lipids emphasizes earlier risk assessment, more personalized ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide 2.4 mg was tied to reduced risk for major adverse cardiovascular events in certain patients with ...

Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, in people with diabetes by as much as 60%, according to a study in The ...

New research shows that small improvements to sleep, diet quality, and physical activity, made in combination, are associated ...

Cardiology groups say adults as young as 30 should assess cholesterol risk and consider treatment to prevent heart attacks ...

The SMART2 model for estimating recurrent CV risk is well-calibrated overall but slightly underestimates risk in patients ...